Product Description
a cocktail of threeÊS. aureus MyoviridaeÊphages, made to current good manufacturing practice (cGMP) standards, and which has undergone two phase I clinical trials, in treatment of multidrug-resistant (MDR)ÊS. aureusÊinfections. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346408/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Nasal
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innoviva
Company Location: BURLINGAME CA 94010
Company CEO: Pavel Raifeld
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Sinusitis
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| nil | P2 |
Completed |
Sinusitis |
2016-09-16 |
|
| AB-SA01-01 | P1 |
Completed |
Healthy Volunteers |
2016-08-01 |
|
| AB-SA01-EAP01 | N/A |
No longer available |
Other |
None |